Project Grant R44CA240019

This Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports the development of an automated multimodal, multiscale algorithm for cervical cancer screening in low- and middle-income countries (LMICs). The $104,278 award, granted on January 11, 2026, will fund the following key objectives: Design a multimodal image registration algorithm to spatially correlate and combine information from widefield colposcope images and...

The National Cancer Institute (NCI) awarded Oraliva, Inc. a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel, low-cost, and fully integrated point-of-care (POC) gynecological screening test. The grant, awarded on September 1, 2025, with a completion date of August 31, 2026, will enable Oraliva to leverage its proprietary AI-linked cytomics-on-a-chip technology (ONC-INCYT) to create a rapid, POC diagnostic tool that can accurately...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...

This federal Project Grant award of $317,420 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate a patient-ready callascope device for cervical imaging and cancer prevention in low- and middle-income countries (LMICs). The primary focus is on creating point-of-care solutions for screening, diagnosis, and treatment that can be delivered by community health workers and midwives, thereby increasing access to care. Key...

The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...

This $593,383 Project Grant, awarded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The primary awardee, The Methodist Hospital Research Institute, is collaborating with The Johns Hopkins University on this project. The proposed system aims to eliminate...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop a digital pathology "laboratory-in-a-box" solution that produces and analyzes high-resolution, 3D digital pathology images at the point of care within seconds. The solution combines rapid confocal imaging hardware with AI-enabled software to automatically recolorize and interpret the digital...

The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,021,347 to Vigilant Laboratories LLC to develop a low-cost, point-of-care early detection test for oral cancer in low-resource settings. The key products to be delivered include: Prototypes of test strips for three biomarkers (CD44, total protein, and p16) to enable a commercializable point-of-care test. Vigilant Laboratories will work with a manufacturing partner,...

This federal Project Grant award, valued at $306,872 and provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to develop a new imaging system termed the Multi-Camera Array Scanner (MCAS). The MCAS will enable rapid 3D digitization and automated analysis of thick fine-needle aspiration (FNA) cytology smears, which are a critical first step in the cancer diagnosis pipeline. The project is a collaboration between Ramona Optics Inc., a small...